Literature DB >> 1517374

Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis.

H De Boer1, G J Blok, H J Voerman, P M De Vries, E A van der Veen.   

Abstract

Anthropometry and bioimpedance analysis (BIA) were used to assess body composition in 42 GH-deficient (GHD) adult males (mean age, 27.2 +/- 4.7 yr). During childhood, all patients had received GH treatment for a mean period of 8.4 +/- 3.8 yr. At the start of this study, GH therapy had been discontinued for a mean period of 7.5 +/- 4.5 yr. Eighteen patients had isolated GH deficiency (I-GHD). Twenty-four patients had multiple pituitary hormone deficiencies (M-PHD), substituted adequately. Compared to age- and sex-matched controls, the sum of skinfolds measured at 7 different sites was significantly higher in I-GHD and M-PHD patients [controls, 73.1 +/- 25.4 mm; I-GHD patients, 102.1 +/- 37.7 mm (P less than 0.001); M-PHD patients, 126.8 +/- 35.4 mm (P less than 0.001)]. The increase in sc fat deposition was most pronounced on the trunk, particularly in the breast and abdominal area. Total body muscle mass was significantly lower in GHD patients (P less than 0.001). In patients, body muscle mass and plasma somatomedin-C level were positively correlated (r = 0.43; P less than 0.005). Total body resistance measured by whole body BIA was significantly higher in the patient group and was negatively correlated with plasma somatomedin-C (r = -0.53; P less than 0.001). The high resistance values observed in GHD patients could only in part be explained by their lower lean body mass. The most important cause, however, was an increase in specific electrical resistance of the lean body mass (LBM), reflecting relative dehydration. We conclude that GH deficiency in adult males is associated with an increase in sc fat and a decrease in body muscle mass. In addition, there is a qualitative change in LBM. The BIA data indicate that in these patients, the hydration state of the LBM is lower than normal, due to a decrease in extracellular water.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517374     DOI: 10.1210/jcem.75.3.1517374

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  IGF-1 has sexually dimorphic, pleiotropic, and time-dependent effects on healthspan, pathology, and lifespan.

Authors:  Nicole M Ashpole; Sreemathi Logan; Andriy Yabluchanskiy; Matthew C Mitschelen; Han Yan; Julie A Farley; Erik L Hodges; Zoltan Ungvari; Anna Csiszar; Sixia Chen; Constantin Georgescu; Gene B Hubbard; Yuji Ikeno; William E Sonntag
Journal:  Geroscience       Date:  2017-04-13       Impact factor: 7.713

3.  Correlation of increased plasma osteoprotegerin and cardiovascular risk factors in patients with adult growth hormone deficiency.

Authors:  Jiajia Xia; Linman Li; Wei Ren; Xiaoya Zheng; Chan Liu; Jinchao Li; Tingying Chen; Xiaofeng Li; Lingli Wang; Yumei Hu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

4.  Growth hormone status predicts left ventricular mass in patients after cure of acromegaly.

Authors:  Tamara L Wexler; Ronen Durst; David McCarty; Michael H Picard; Lindsay Gunnell; Zehra Omer; Pouneh Fazeli; Karen K Miller; Anne Klibanski
Journal:  Growth Horm IGF Res       Date:  2010-07-03       Impact factor: 2.372

Review 5.  The Gordon Wilson Lecture. Growth hormone replacement in adults and other uses.

Authors:  M L Vance
Journal:  Trans Am Clin Climatol Assoc       Date:  1998

6.  The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency.

Authors:  Alessandro Ciresi; Stefano Radellini; Valentina Guarnotta; Carla Giordano
Journal:  Endocrine       Date:  2016-08-13       Impact factor: 3.633

7.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

8.  Changes in insulin levels following 6-month treatment with recombinant human growth hormone in growth hormone-deficient adults.

Authors:  D Valle; M N D Di Minno; V Palmieri; S Pezzullo; F Cirillo; C Di Somma; G Di Minno; G Lombardi
Journal:  J Endocrinol Invest       Date:  2009-07-17       Impact factor: 4.256

9.  Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia - From the St. Jude Lifetime Cohort.

Authors:  Kerri A Nottage; Kirsten K Ness; Chenghong Li; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson
Journal:  Br J Haematol       Date:  2014-01-27       Impact factor: 6.998

10.  Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.

Authors:  Janet Lo; Sung Min You; Bridget Canavan; James Liebau; Greg Beltrani; Polyxeni Koutkia; Linda Hemphill; Hang Lee; Steven Grinspoon
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.